» Articles » PMID: 34395557

Protective Effects of Thyroid Hormone Deprivation on Progression of Maladaptive Cardiac Hypertrophy and Heart Failure

Overview
Date 2021 Aug 16
PMID 34395557
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid hormones (TH) play a central role for cardiac function. TH influence heart rate and cardiac contractility, and altered thyroid function is associated with increased cardiovascular morbidity and mortality. The precise role of TH in onset and progression of heart failure still requires clarification. Chronic left ventricular pressure overload was induced in mouse hearts by transverse aortic constriction (TAC). One week after TAC, alteration of TH status was induced and the impact on cardiac disease progression was studied longitudinally over 4 weeks in mice with hypo- or hyperthyroidism and was compared to euthyroid TAC controls. Serial assessment was performed for heart function (2D M-mode echocardiography), heart morphology (weight, fibrosis, and cardiomyocyte cross-sectional area), and molecular changes in heart tissues (TH target gene expression, apoptosis, and mTOR activation) at 2 and 4 weeks. In diseased heart, subsequent TH restriction stopped progression of maladaptive cardiac hypertrophy and improved cardiac function. In contrast and compared to euthyroid TAC controls, increased TH availability after TAC propelled maladaptive cardiac growth and development of heart failure. This was accompanied by a rise in cardiomyocyte apoptosis and mTOR pathway activation. This study shows, for the first time, a protective effect of TH deprivation against progression of pathological cardiac hypertrophy and development of congestive heart failure in mice with left ventricular pressure overload. Whether this also applies to the human situation needs to be determined in clinical studies and would infer a critical re-thinking of management of TH status in patients with hypertensive heart disease.

Citing Articles

FLRT3 and TGF-β/SMAD4 signalling: Impacts on apoptosis, autophagy and ion channels in supraventricular tachycardia.

Pang Y, Xu Y, Chen Q, Cheng K, Ling Y, Jang J J Cell Mol Med. 2024; 28(7):e18237.

PMID: 38509727 PMC: 10955158. DOI: 10.1111/jcmm.18237.


Cardiac recovery from pressure overload is not altered by thyroid hormone status in old mice.

Kerp H, Gassen J, Grund S, Hones G, Dorr S, Mittag J Front Endocrinol (Lausanne). 2024; 15:1339741.

PMID: 38455657 PMC: 10917895. DOI: 10.3389/fendo.2024.1339741.


Thyroid hormone-dependent oligodendroglial cell lineage genomic and non-genomic signaling through integrin receptors.

Emamnejad R, Dass M, Mahlis M, Bozkurt S, Ye S, Pagnin M Front Pharmacol. 2022; 13:934971.

PMID: 36133808 PMC: 9483185. DOI: 10.3389/fphar.2022.934971.


Qige Huxin Formula Attenuates Isoprenaline-Induced Cardiac Fibrosis in Mice via Modulating Gut Microbiota and Protecting Intestinal Integrity.

Shi L, Du X, Zuo B, Hu J, Cao W Evid Based Complement Alternat Med. 2022; 2022:2894659.

PMID: 35911163 PMC: 9328975. DOI: 10.1155/2022/2894659.


3,5-T2-an Endogenous Thyroid Hormone Metabolite as Promising Lead Substance in Anti-Steatotic Drug Development?.

Sane R, Wirth E, Kohrle J Metabolites. 2022; 12(7).

PMID: 35888706 PMC: 9322486. DOI: 10.3390/metabo12070582.


References
1.
Klein I, Danzi S . Thyroid disease and the heart. Circulation. 2007; 116(15):1725-35. DOI: 10.1161/CIRCULATIONAHA.106.678326. View

2.
Zwaveling J, Batink H, de Jong J, Winkler Prins E, Pfaffendorf M, van Zwieten P . Thyroid hormone modulates inotropic responses, alpha-adrenoceptor density and catecholamine concentrations in the rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1996; 354(6):755-64. DOI: 10.1007/BF00166902. View

3.
Jonklaas J, Bianco A, Bauer A, Burman K, Cappola A, Celi F . Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014; 24(12):1670-751. PMC: 4267409. DOI: 10.1089/thy.2014.0028. View

4.
Shimizu I, Minamino T . Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol. 2016; 97:245-62. DOI: 10.1016/j.yjmcc.2016.06.001. View

5.
Holt E, Sjaastad I, Lunde P, Christensen G, Sejersted O . Thyroid hormone control of contraction and the Ca(2+)-ATPase/phospholamban complex in adult rat ventricular myocytes. J Mol Cell Cardiol. 1999; 31(3):645-56. DOI: 10.1006/jmcc.1998.0900. View